ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

International Cancer Program Enthusiasm A Spinoff From U.S. Program, XIIth Congress Demonstrates

October 20, 1978

Decision On Status Of Frederickson, DeVita Due In Month, Schweiker Says

May 1, 1981

Amgen Pays $24.9 Million To Settle Kickback Charges

April 19, 2013

Personal letters: mixed reviews of Donald Pinkel’s article on Childhood Lymphocytic Leukemia

May 6, 2021

Triple-Negative Breast Cancer Increases With Number of Births

March 25, 2011

Community Based Control Program Taking Final Shape

April 29, 1977